OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
22
Frequently Asked Questions
What is Market Cap of OncoMed Pharmaceuticals, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. OncoMed Pharmaceuticals, Inc. market cap is N/A.
What is the 52-week high for OncoMed Pharmaceuticals, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. OncoMed Pharmaceuticals, Inc. 52 week high is N/A as of September 16, 2025.
What is the 52-week low for OncoMed Pharmaceuticals, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. OncoMed Pharmaceuticals, Inc. 52 week low is N/A as of September 16, 2025.
What is OncoMed Pharmaceuticals, Inc. stock price today?
OncoMed Pharmaceuticals, Inc. stock price today is $0.89.
What was OncoMed Pharmaceuticals, Inc. stock price yesterday?
OncoMed Pharmaceuticals, Inc. stock price yesterday was $0.9399.
What is the PE ratio of OncoMed Pharmaceuticals, Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. OncoMed Pharmaceuticals, Inc.’s P/E ratio is None.
What is the Price-to-Book ratio of OncoMed Pharmaceuticals, Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. OncoMed Pharmaceuticals, Inc. P/B ratio is None.
What is OncoMed Pharmaceuticals, Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. OncoMed Pharmaceuticals, Inc.'s EBITDA is 4.38.
What is the 50-day moving average of OncoMed Pharmaceuticals, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. OncoMed Pharmaceuticals, Inc. 50-day moving average is N/A.
How many employess does OncoMed Pharmaceuticals, Inc. has?
